Literature DB >> 11406843

A closer look at combining data among a small number of binomial experiments.

D Malec1.   

Abstract

In a regulatory environment, the regulators and the regulated may not be able to agree on the use of subjective prior information for a clinical trial. The use of a data-based prior offers a greater possibility for agreement, however, the degree of importance given to the prior data may still be contentious. The use of a hierarchical model to link the prior data and the current trial is shown to provide a relatively objective method for assigning weight to the prior data. Using a series of examples combining two binomial experiments, the effect of a hierarchical model on estimating rates, on the degree to which data is combined and on hypothesis testing is illustrated. In addition, the phenomenon in which combining data reduces the precision is explained. Simpler models based on finite mixtures of beta distributions are shown to work as well as the more computationally intensive, continuous mixtures. Lastly, an example combining three concurrent studies is illustrated. Published in 2001 by John Wiley & Sons, Ltd.

Mesh:

Year:  2001        PMID: 11406843     DOI: 10.1002/sim.782

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee
Journal:  Pharm Stat       Date:  2021-05-19       Impact factor: 1.234

2.  A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.

Authors:  Dominic J Allocco; Louis A Cannon; Amy Britt; John E Heil; Andrey Nersesov; Scott Wehrenberg; Keith D Dawkins; Dean J Kereiakes
Journal:  Trials       Date:  2010-01-07       Impact factor: 2.279

3.  Using phase II data for the analysis of phase III studies: An application in rare diseases.

Authors:  Simon Wandel; Beat Neuenschwander; Christian Röver; Tim Friede
Journal:  Clin Trials       Date:  2017-04-07       Impact factor: 2.486

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.